Differential Immunoexpression of Inhibitory Immune Checkpoint Molecules and Clinicopathological Correlates in Keratoacanthoma, Primary Cutaneous Squamous Cell Carcinoma and Metastases
Lonsdorf, Anke S, Edelmann, Dominic, Albrecht, Thomas, Brobeil, Alexander, Labrenz, Jannik, Johanning, Moritz, Schlenk, Richard F, Goeppert, Benjamin, Enk, Alexander H, Toberer, Ferdinand
Published in Acta dermato-venereologica (07.02.2024)
Published in Acta dermato-venereologica (07.02.2024)
Get full text
Journal Article
Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease
Heitmann, Jonas S., Schlenk, Richard F., Dörfel, Daniela, Kayser, Sabine, Döhner, Konstanze, Heuser, Michael, Thol, Felicitas, Kapp-Schwoerer, Silke, Labrenz, Jannik, Edelmann, Dominic, Märklin, Melanie, Vogel, Wichard, Bethge, Wolfgang, Walz, Juliane S., Große-Hovest, Ludger, Steiner, Martin, Jung, Gundram, Salih, Helmut R.
Published in Journal of hematology and oncology (17.08.2023)
Published in Journal of hematology and oncology (17.08.2023)
Get full text
Journal Article
Performance of phase‐I dose finding designs with and without a run‐in intra‐patient dose escalation stage
Labrenz, Jannik, Edelmann, Dominic, Heitmann, Jonas S., Salih, Helmut R., Kopp‐Schneider, Annette, Schlenk, Richard F.
Published in Pharmaceutical statistics : the journal of the pharmaceutical industry (01.03.2023)
Published in Pharmaceutical statistics : the journal of the pharmaceutical industry (01.03.2023)
Get full text
Journal Article
Abstract CT141: CC-1, a bispecific PSMAxCD3 antibody for treatment of prostate carcinoma: Results of the ongoing phase I dose escalation trial
Heitmann, Jonas S., Walz, Juliane S., Pflügler, Martin, Marconato, Maddalena, Tegeler, Christian M., Reusch, Julia, Labrenz, Jannik, Schlenk, Richard, Jung, Gundram, Salih, Helmut
Published in Cancer research (Chicago, Ill.) (15.06.2022)
Published in Cancer research (Chicago, Ill.) (15.06.2022)
Get full text
Journal Article